Information Provided By: 
Fly News Breaks for September 29, 2015
NVAX
Sep 29, 2015 | 11:04 EDT
After Novavax released top-line Phase II RSV-F vaccine data, Piper Jaffray analyst Edward Tenthoff said he is not sure that this vaccine will have dramatic uptake in pregnant women. He lowered his price target on Novavax to $15 from $17 to account for a reduced RSV maternal immunization forecast, but maintains on Overweight rating on the stock, citing the "blockbuster potential" of the company's RSV vaccine in the elderly.
News For NVAX From the Last 2 Days
There are no results for your query NVAX
